On the basis of a previous experience suggesting that daunorubicin dose in induction was an independent prognostic factor in adult ALL, we designed a chemotherapeutic regimen 
Introduction
Although considerable progress has been achieved in the treatment of acute lymphoblastic leukemia (ALL) in childhood, the cure rate of adult ALL is still largely unsatisfactory, 1,2 the long-term event-free survival (EFS) ranging between 25 and 40% in recently published trials. [3] [4] [5] [6] [7] [8] [9] In a previous study we found that the dose and dose-intensity of daunorubicin (DNM) delivered during the induction period represented the major prognostic factor for the outcome of adult ALL. 10 On the basis of those results, in order to possibly improve the long-term results in adult ALL, we designed a phase II chemotherapeutic regimen characterized by elevated dosage of DNM delivered during the early phase of induction and high dose of Ara-C (HiDAC) in postremission. The elevated doses of DNM and post-remission HiDAC were given in the context of an otherwise conventional ALL treatment approach, including chemo-and radioprophylaxis of the central nervous system (CNS) involvement, and periodical re-inductions over a 3-year maintenance period.
The rationale for this intensive approach was that a more intensive induction and early post-remission therapy might lead to a more rapid destruction of leukemic cells, before the development of drug resistance.
Here we report the results obtained with such a treatment strategy (protocol ALLVR589) in 60 consecutive adult ALL patients, observed in a single institution over an 8-year period with a median follow-up of 44 months.
Patients and methods

Patients
Between 1989 and 1996, 60 consecutive untreated adults under 72 years of age with a diagnosis of T or B-lineage ALL entered the ALLVR589 protocol after informed consent. Patients with mature B-ALL (FAB L3, TdT − , slg + ) were treated with a different intensive pediatric-derived protocol as previously reported. 11 All the enrolled patients were evaluable for treatment outcome. Severe cardiac (left ventricular ejection fraction Ͻ50%) and hepatic failure (bilirubin, GPT and GOT more than 2.5 times the normal value) were reasons for exclusions (two elderly patients, aged 60 and 70, excluded due to hepatic failure at diagnosis). In all cases the diagnosis was based on peripheral blood and bone marrow (BM) morphological examination, conventional cytochemistry, and immunophenotyping. This latter was performed by flow cytometry using a panel of monoclonal antibodies against immaturity, lymphoid B and T, and myeloid markers. They included HLA DR, CD34, TdT, CD10, CD19, CD20, slg, cytoplasmic , CD7, CD1, cytoplasmic and membrane CD3, CD4, CD8, CD13 and CD33. Complete physical examination, chest Xray, abdominal echography, chromosome analysis and bcr/abl gene rearrangement investigation of BM blasts and an extended panel of laboratory tests were performed before starting treatment. The patients main clinical and laboratory parameters at presentation are reported in Table 1 . Chromosome abnormalities were present in 23 out of 38 cases in Table 1 Patients' characteristics at presentation . At the end of induction therapy, following complete hematologic recovery, patients aged 14-50 years received two consolidation cycles with high-dose Ara-C (HiDAC), whereas patients between 51 and 60 years received only one cycle, and those over 60 did not receive any. Starting with patient 28, a 23-year-old man presenting an extensive extramedullary disease, i.v. etoposide (VP-16) (150 mg/m 2 /day for 3 days) was added to HiDAC in patients younger than 60. Etoposide was incorporated into the consolidation regimen
Figure 1
Protocol ALLVR589: induction, intensification, CNS prophylaxis.
based on the demonstration of its usefulness when combined with Ara-C. 12 Marrow aplasia was not prolonged and no additional major toxicity was observed as compared to the previous patients treated with HiDAC alone. Maintenance therapy was continued for a total of 3 years. To avoid the risk of cardiac toxicity, DNM administration during reinduction was stopped when the total DNM dosage reached 550 mg/m 2 . Seven patients (one refractory to the induction therapy, two who achieved CR slowly, four relapsed) underwent allogeneic bone marrow transplantation. The two slow responders, who have been transplanted in first CR, were censored for OS and EFS at the time of BMT. Adequate hydration, allopurinol, antibacterial (ciprofloxacin 500 mg twice a day, orally) and antifungal prophylaxis (itraconazole, 200 mg/day orally plus amphotericin B 10 mg/day nasal spray), were delivered during induction and intensification periods. Diagnostic lumbar puncture was not performed at presentation, with the only exception being a case with clinical evidence of CNS involvement who received early intrathecal (i.t.) administration of methotrexate (MTX) during induction. All other cases had diagnostic lumbar puncture, associated with i.t. introduction of 15 mg MTX, at the same time as the third cycle of DNM in a phase of complete remission (CR). BM aspiration was routinely performed before each DNM cycle during induction and before consolidation therapy. Further on it was only performed in the presence of clinical and/or hematological findings suggesting a possible relapse. Hematopoietic growth factors were not used.
Serum amylase and coagulation tests were strictly monitored during asparaginase (l-ASE) administration. Fibrinogen cryoprecipitate was administered whenever fibrinogen levels were Ͻ80 mg/dl and associated with platelet count Ͻ30 × 10 9 /l. Complete clinical and hematological evaluation, including blood and BM smears and lumbar puncture, was performed at the end of treatment.
Figure 2
Protocol ALLVR589: maintenance.
Criteria for response CR was defined on the basis of the absence of any clinical evidence of disease in association with Ͼ1.5 × 10 9 /l granulocytes (PMN), Ͼ100 × 10 9 /l platelets, 12 g/dl hemoglobin and normocellular BM with less than 5% blasts. Slow responders were defined by achieving the CR only after the third DNM cycle.
Statistical methods
The primary study end points were the achievement of CR, duration of first CR, overall survival (OS) and event-free survival (EFS). Differences in CR rate among patient groups were analyzed using Fisher's exact test. OS was defined as the time from study entry to death or date of the last follow-up. EFS was defined as survival without (1) remission failure; (2) relapse of any kind; (3) development of a life-threatening secondary malignancy; (4) death of any cause. Disease-free survival (DFS) was defined as the survival from the CR and (1) relapse or (2) last observation. No patient was lost to follow-up.
The patients who underwent allogeneic BMT in first complete remission were censored for the analysis of CR duration and OS at the time of transplantation. Probability of CR duration, OS and EFS were estimated by the Kaplan-Meier method. 13 The analysis was made according to data available at 10 July 1997.
Results
DNM dose and dose intensity
The median dose of DNM actually delivered was 257.5 mg/m 2 (range 177-292; 95% of intended dosage) and the median dose intensity was 38 mg/m 2 /week (range 19-67). The target dose was reached in 37 out of 57 evaluable patients. Three patients were not evaluable because of early death. Reasons for dose reduction during induction therapy in the other patients were: age Ͼ60 (six cases), infections (10 cases), uric acid nephropathy at diagnosis (two cases), toxic hepatitis (two cases). Dose reduction was always done by reducing the daily dose over the three cycles. Four young patients, with poor prognostic factors were given a DNM dose higher than 270 mg/m 2 without relevant side-effects. WBC count nadir occurred after a median of 13.5 days following the first DNM cycle (median PMN count 0.216 × 10 9 /l, with an absolute count below 0.1 × 10 9 /l in 57% of patients) and of 12 days after the second DNM cycle (median PMN count 0.713 × 10 9 /l) with an absolute PMN count below 0.1 × 10 9 /l in 23% of patients). No patients had profound neutropenia following the third DNM cycle having a WBC nadir on the 12th day, with a PMN median count of 1.047 × 10 9 /l. No patients (with the exception of the one with CNS disease at presentation) received therapy with off-protocol schedules or drugs.
The median time required to complete the induction was 48 days (range 32-99). The long median hospitalization duration was influenced by the occurrence of some severe infectious complications, particularly fungal pneumonia, which required a prolonged antifungal treatment.
Outcome CR was achieved in 56/60 (93%) patients, one had refractory disease and three died early before the assessment of the response due to Pseudomonas septicemia (1) , CNS Aspergillosis (1) and Staphylococcus aureus septicemia and pneumonia (1). The CR was reached after the first cycle of DNM in 44/56 (78.5%) complete responders, after the second in 10 and after the third in two patients. Four patients died in CR, two immediately after CR achievement due to Gram-negative septicemia, one at +14 months due to bowel diverticulum perforation and the fourth at +9 months following the development of a colon carcinoma. A bone marrow relapse occurred in 19 of 56 (34%) patients who achieved CR. Five relapses occurred in PhЈ-positive patients. No CNS relapses were observed. The median time to relapse was 11 months (range 3-47), the majority of relapses (13/19, 68%) being observed within 12 months from CR achievement.
The median duration of DFS for the 56 patients who achie ved CR is 34 months (range 1-99). At present, 23/60 (38%) patients have completed the 3-year maintenance therapy and are off-therapy in continuous CR (median follow-up from the diagnosis 63 months; range 38-100), 18 of them having a CCR of more than 48 months (in 10 patients the CCR exceeds 72 months). Statistical analysis indicates that 33/60 patients (55%) are estimated to remain event-free at 6 years. The OS and EFS curves are reported in Figures 3 and 4 , respectively.
CR and relapse rate in B or T-lineage patients were 91 vs 96%, (P = 0.91) and 37.5 vs 29%, respectively). Excluding B PhЈ-bcr/abl-positive cases, relapses in B-lineage were 26.9% as compared to 29% in T-lineage.
Figure 3
Protocol ALLVR589: overall survival.
Figure 4
Protocol ALLVR589: event-free survival.
Chromosome abnormalities could not be individually evaluated as risk factors in the present study due to their sporadic presentation, with the notable exception of the seven PhЈ-bcr/abl-positive patients, five of whom relapsed after a median follow-up of 5 months (range [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] . The two remaining patients died early, before the assessment of CR and in early CR, respectively.
Patients under 50 years (46 cases) experienced a similar CR rate and lower relapses than those older than 50 (14 cases): (CR 96 vs 86%, P = 0.22, and relapses 27 vs 58%). If PhЈ-bcr/abl-positive cases were not considered, CR were 95 vs 89%, P = 0.43, and relapses 25 vs 37.5%). Patients with a leukocyte count Ͼ30 × 10 9 /l had a higher relapse rate than those with a count Ͻ30 × 10 9 /l (45 vs 28%).
Side-effects
Overall in 38/60 patients (63%) the following side-effects were observed. Infectious complications occurred in 19/60 cases (32%). These included 11 bacteremias (six due to Gramnegative; four complicated by pneumonia and two by septic shock), two of which were fatal, and eight deep fungal infections (seven pneumonia, eventually cured, and one fatal CNS infection). Vincristine (VCR)-related peripheral neuropathy was observed in six patients (5/6 reversible) and paralytic ileus in nine (all reversible). Two patients had transient toxic hepatitis. A 70-year-old PhЈ patient died of pulmonary embolism early during induction therapy, before starting l-ASE treatment. An additional thrombotic event has been observed in one patient. The 47-year-old patient with CNS disease at presentation who was given intrathecal administration of MTX during the induction (total eight doses), followed by high-dose MTX and HiDAC, developed a transverse myelitis, which subsequently only partially and slowly improved. At present, the patient is off-therapy in first CR at 38 months from diagnosis. He received a maintenance treatment with a modified schedule without VCR and MTX administration. We did not find any sign of toxicity in a cardiac follow-up function study performed in all the patients who completed the total DNM dose. 14 Moreover, to avoid the risk of a DNM related cardio toxicity, the protocol set a maximum cumulative dose (over the whole 3-year period) of 550 mg/m 2 .
Discussion
Protocol ALLVR589, mainly designed to deliver elevated doses of DNM during the early phase of induction, has resulted in 93% CR rate with an estimated EFS at 6 years of 55% in a series of 60 consecutive adult ALL patients. These encouraging results in adults with ALL approximate the salutary outcome in childhood ALL, 1,2 and may represent a clinical advance over previous regimens, where EFS ranges from 25-40%, 9, 15, 16 if validated in large-scale clinical trials and extended follow-up.
Although DNM is included in most therapeutic plans for adult ALL, its specific role in the setting of ALL polychemotherapy regimens is difficult to define. 3, 6, 17, 18 This is mainly because DNM doses are largely variable in different studies 15, [19] [20] [21] [22] and few data from randomized studies are available. Overall, available studies suggest that high early dose and intensified dose intensity of DNM during induction obtain better results. 9, 10, 20, 22 In our previous study, the dosage and dose intensity of DNM delivered in induction to 86 consecutive adult patients with ALL appeared as the major prognostic factors for longterm outcome. 10 Following this observation, we decided to escalate DNM doses in the induction phase up to the intended dose of 270 mg/m 2 , with two main objectives: (1) of increasing the CR rate; (2) decreasing the relapse rate, the major problem of adult ALL patients. The DNM dose in the ALLVR589 protocol is higher than that used by other recent antracycline-containing protocols. 15 DNM dose actually delivered during induction in the present study was very close to the intended one (average: 95%). Indeed, although the relatively wide DNM range 177-292 mg/m 2 reported, the large majority of the patients received a dose inside a narrow range, very close to the median indicated. Probably this is the reason why we failed to find differences in outcome between the two groups of patients (ie patients who received the target DNM dose vs patients who did not as well as patients who received the median DNM dose vs patients who did not). We did not observe any difference in the outcome of patients who received VP-16 as compared to patients who did not.
The therapeutic schedule was feasible, however, the therapy-related side-effects were not negligible requiring a careful supportive therapy and a median hospitalization for the induction period of 48 days. With such support, early deaths were relatively few (5/60, 8%), and lower than those observed in our previous experience. 10 Although our study design does not allow evaluation of the specific contribution of DNM and intensive post-induction therapy to the observed results, it is tempting to postulate that the intensity of DNM dose during induction plays an important role in the clinical outcome, in particular the low incidence of cases resistant to treatment (1/60, 2%) and rapid achievement of CR in most cases. From the more important biological point of view, the positive effect of intensive induction and post-remission treatment on the long-term outcome, with a resultant lower frequency of relapses, may be related in part to the rapid killing of leukemic cells before the development of drug resistance. 15 We are aware that the high proportion of event-free survivors observed might be at least partially related to the relatively low incidence (7/60, 12% cases) of PhЈ and bcr/ablpositive cases. This is due to the frequency of T-ALL cases (42%) which is somewhat higher than usually observed in most adult ALL series (25-30%). Considering the number of B-lineage ALL, the percentage of PhЈ and bcr/abl+ cases was 20%, slightly inferior to that currently observed in recent series. Indeed, of the seven PhЈ-bcr/abl+ patients, five had a poor outcome since all relapsed within 14 months from CR achievement, the two remaining died early before the assessment of CR and in early CR, respectively. For these patients the efficacy of more intensive therapy is doubtful and alternative new strategies are warranted.
High WBC count did not influence the CR achievement but the long-term outcome. Other risk factors, such as immunophenotype attribution and time to achieve the CR have been apparently overwhelmed by the efficacy of therapy. Even age failed to play a significant role on outcome, when PhЈ-bcr/ablpositive patients were excluded from analysis.
An additional relevant finding that has emerged from our study is represented by the absence of relapses in the traditional 'sanctuaries' such as CNS and testis. This suggests that our treatment approach is suitable to prevent the involvement of sanctuaries, a mandatory step for successful long-term results in ALL.
Taken together, our results suggest that increasing DNM dose in induction is one of the possible approaches to improve the CR rate and to decrease relapse occurrence. Clearly, these conclusions must be validated by a larger series of cases in the context of a multi-institutional study. This protocol is currently tested in an Italian large multicenter trial (GIMEMA (Chairman: Prof Franco Mandelli)). The study is ongoing.
